283. Targeted Delivery of C/EBPα-Small Activation RNA (saRNA) by RNA Aptamer Inhibits the Growth of Pancreatic Ductal Adenocarcinoma (PDAC) in Vivo

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33892-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Corrigendum to “Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-Specific RNA Aptamers Inhibits Tumor Growth in Vivo”

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

International Journal of Medical Sciences
Medicine
2020English

A Thrombin-Activated PAR-1 Pathway Drives Pancreatic Ductal Adenocarcinoma (PDAC) Growth and Metastasis

Journal of Purdue Undergraduate Research
2019English

CCAT2 Is an Oncogenic Long Non-Coding RNA in Pancreatic Ductal Adenocarcinoma

Biological Research
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgricultural
2018English

A Small Molecule FAK Kinase Inhibitor, GSK2256098, Inhibits Growth and Survival of Pancreatic Ductal Adenocarcinoma Cells

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2014English

MEX3A Knockdown Inhibits the Development of Pancreatic Ductal Adenocarcinoma

Cancer Cell International
Cancer ResearchOncologyGenetics
2020English

Targeted, Systemic Delivery of Therapeutic Small Interfering RNA Nanoparticles

Science-Business eXchange
2009English

A U87-EGFRvIII Cell-Specific Aptamer Mediates Small Interfering RNA Delivery

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2014English

RNA Interference Against Hec1 Inhibits Tumor Growth in Vivo

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy